Veracyte | VCYT - Current Liabilities


Veracyte reported $56.11M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Agenus USD 249.24M 74.25M Mar/2026
Agilent USD 2.27B 35M Mar/2026
Anika Therapeutics USD 20.97M 942K Mar/2026
Arrowhead Research USD 295.22M 52.2M Mar/2026
Bruker USD 1.36B 75.9M Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Illumina USD 1.57B 19M Mar/2026
Intrexon USD 23.02M 38K Jun/2024
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Laboratory Of America USD 2.64B 182.5M Mar/2026
Ligand Pharmaceuticals USD 40.67M 3.22M Mar/2026
Myriad Genetics USD 130.2M 3.6M Mar/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Siemens EUR 49.52B 168M Mar/2026
Sonic Healthcare AUD 2.23B 92.84M Dec/2024
Thermo Fisher Scientific USD 14.62B 568M Mar/2026
Veracyte USD 56.11M 3.82M Mar/2026
Waters USD 1.24B 11.8M Dec/2025